|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 305.64 USD | -1.04% |
|
+1.47% | -13.04% |
| 06-05 | Leerink Partners Adjusts Price Target on Stryker to $407 From $410, Maintains Outperform Rating | MT |
| 06-05 | Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca | AN |
Company Valuation: Stryker Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 100,882 | 92,522 | 113,776 | 137,257 | 134,410 | 117,170 | - | - |
| Change | - | -8.29% | 22.97% | 20.64% | -2.07% | -12.83% | - | - |
| Enterprise Value (EV) 1 | 110,335 | 102,451 | 121,655 | 144,952 | 134,410 | 125,998 | 122,637 | 118,764 |
| Change | - | -7.14% | 18.74% | 19.15% | -7.27% | -6.26% | -2.67% | -3.16% |
| P/E Ratio | 51.3x | 39.6x | 36.3x | 46.4x | 41.8x | 24.1x | 21.1x | 18.6x |
| PBR | 6.79x | 5.56x | 6.11x | 6.65x | - | 4.51x | 3.94x | 3.36x |
| PEG | - | 2.1x | 1.1x | -7.81x | 5.07x | 0.5x | 1.5x | 1.4x |
| Capitalization / Revenue | 5.9x | 5.02x | 5.55x | 6.07x | 5.35x | 4.3x | 3.96x | 3.66x |
| EV / Revenue | 6.45x | 5.55x | 5.93x | 6.42x | 5.35x | 4.62x | 4.15x | 3.71x |
| EV / EBITDA | 23.2x | 21.5x | 22.7x | 23.6x | 19x | 16.1x | 14.4x | 12.6x |
| EV / EBIT | 25.2x | 23.4x | 24.6x | 25.4x | 20.4x | 17.4x | 15.3x | 13.4x |
| EV / FCF | 40.3x | 50.3x | 39.2x | 41.6x | 31.4x | 34.3x | 25x | 20.8x |
| FCF Yield | 2.48% | 1.99% | 2.55% | 2.41% | 3.19% | 2.91% | 4% | 4.81% |
| Dividend per Share 2 | 2.585 | 2.835 | 3.05 | 3.24 | - | 3.611 | 3.867 | 4.193 |
| Rate of return | 0.97% | 1.16% | 1.02% | 0.9% | - | 1.18% | 1.27% | 1.37% |
| EPS 2 | 5.21 | 6.17 | 8.25 | 7.76 | 8.4 | 12.69 | 14.46 | 16.41 |
| Distribution rate | 49.6% | 45.9% | 37% | 41.8% | - | 28.5% | 26.7% | 25.6% |
| Net sales 1 | 17,108 | 18,449 | 20,498 | 22,595 | 25,116 | 27,267 | 29,581 | 31,970 |
| EBITDA 1 | 4,753 | 4,755 | 5,348 | 6,142 | 7,064 | 7,805 | 8,537 | 9,456 |
| EBIT 1 | 4,382 | 4,384 | 4,955 | 5,715 | 6,603 | 7,262 | 8,009 | 8,881 |
| Net income 1 | 1,994 | 2,358 | 3,165 | 2,993 | 3,246 | 4,836 | 5,514 | 6,493 |
| Net Debt 1 | 9,453 | 9,929 | 7,879 | 7,695 | - | 8,827 | 5,467 | 1,594 |
| Reference price 2 | 267.42 | 244.49 | 299.46 | 360.05 | 351.47 | 305.64 | 305.64 | 305.64 |
| Nbr of stocks (in thousands) | 377,240 | 378,430 | 379,938 | 381,216 | 382,424 | 383,361 | - | - |
| Announcement Date | 1/27/22 | 1/31/23 | 1/30/24 | 1/28/25 | 1/29/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 24.09x | 4.62x | 16.14x | 1.18% | 117B | |
| 18.71x | 2.37x | 9.08x | 2.72% | 12.86B | |
| -137.85x | 11.24x | -708.32x | -.--% | 7.29B | |
| 20.45x | 9.64x | 15.63x | 2.1% | 4.12B | |
| 17.57x | 4.72x | 9.23x | 3.49% | 1.63B | |
| 85.43x | 13.27x | 47.18x | 0.06% | 1.49B | |
| Average | 4.73x | 7.64x | -101.84x | 1.59% | 24.09B | |
| Weighted average by Cap. | 15.89x | 4.99x | -20.81x | 1.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SYK Stock
- Valuation Stryker Corporation
Select your edition
All financial news and data tailored to specific country editions
